Synaptogenix, Inc.

Calculating rank

USPTO Granted Patents = 6

Forward Citations = 0

Loading Chart...

2 inventors (with patents filed for the assignee):

Daniel L Alkon (6 out of 59 patents)

Thomas J Nelson (4 out of 57 patents)

6 patents: Sort by Forward Citations

1. 12016837 - Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases (2024-06-25),

2. 11826345 - Dosing regimens of PKC activators (2023-11-28),

3. 11820745 - PKC-activating compounds for the treatment of neurodegenerative diseases (2023-11-21),

4. 11390596 - PKC-activating compounds for the treatment of neurodegenerative diseases (2022-07-19),

5. 11273139 - Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases (2022-03-15),

6. 11045447 - Methods for inducing synaptogenesis with synaptic growth factor activating compounds (2021-06-29),

Company Overview

Synaptogenix, Inc. is a biopharmaceutical company focused on the development of novel therapies for neurodegenerative diseases. The company's lead drug candidate, Bryostatin-1, is being investigated for its potential to treat Alzheimer's disease and other cognitive disorders. Through its innovative research and strategic partnerships, Synaptogenix aims to improve the lives of patients suffering from debilitating neurological conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

6 Patents

#1,029 in New York, NY

#2,698 in New York

#45,030 in US

New York, NY, United States of America